{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:34:30Z","timestamp":1761057270401},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1997,4,1]],"date-time":"1997-04-01T00:00:00Z","timestamp":859852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":8305,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1997,4]]},"DOI":"10.1023\/a:1008287814252","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T13:47:34Z","timestamp":1040564854000},"page":"373-378","source":"Crossref","is-referenced-by-count":6,"title":["5-Fluorouracil, interferon-\u03b1-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study"],"prefix":"10.1016","volume":"8","author":[{"given":"P.A.","family":"Kosmidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bacoyiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Tsavaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Milathianakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Skarlos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008287814252_bb0060","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","article-title":"Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urotheliunr Efficacy and patterns of response and relapse","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"key":"10.1023\/A:1008287814252_bb0065","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.1990.8.6.1050","article-title":"A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors","volume":"8","author":"Logothetis","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008287814252_bb0070","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008287814252_bb0075","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1200\/JCO.1985.3.11.1463","article-title":"Cisplatin, methotrexate and vinblastine (CMV): An effetive chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group study","volume":"3","author":"Harker","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008287814252_bb0080","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/1097-0142(19870801)60:3+<574::AID-CNCR2820601524>3.0.CO;2-C","article-title":"Chemotherapy of urothelial tract tumors","volume":"60","author":"Yagoda","year":"1987","journal-title":"Cancer"},{"key":"10.1023\/A:1008287814252_bb0085","first-page":"395","article-title":"Phase II study of interferon-\u03b1-2A for tumors of urogenital tract","volume":"1","author":"Niijima","year":"1985","journal-title":"Jpn Clin Med Pharmacol"},{"key":"10.1023\/A:1008287814252_bb0090","first-page":"569","article-title":"Interferon (IFN) modulates the activity 5-fluorouracil against two human colon cancer cell lines","volume":"30","author":"Wadler","year":"1989","journal-title":"Proc Am Assn Cancer Res"},{"key":"10.1023\/A:1008287814252_bb0095","first-page":"4868","article-title":"Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites","volume":"48","author":"Elias","year":"1988","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008287814252_bb0100","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.1989.7.12.1769","article-title":"Fluorouracil and recombinant alfa-2-interferon: An active regimen against advanced colorectal carcinoma","volume":"7","author":"Wadler","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008287814252_bb0105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/oxfordjournals.annonc.a057773","article-title":"Potentiation of cisplatin by alpha-interferon in advanced non-small cell lung cancer (NSCLC): A phase II study","volume":"1","author":"Bowman","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008287814252_bb0110","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/1097-0142(19840501)53:9<1819::AID-CNCR2820530903>3.0.CO;2-R","article-title":"Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck","volume":"53","author":"Kish","year":"1984","journal-title":"Cancer"},{"key":"10.1023\/A:1008287814252_bb0115","first-page":"475","article-title":"Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: Analysis of cisplatin and\/or 5-fluorouracil in an in vivo survival model","volume":"54","author":"Keane","year":"1994","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008287814252_bb0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jnci\/83.4.285","article-title":"Fluorouracil and recombinant human interferon alfa-2A in the treatment of metastatic chemotherapy-refractory urothelial tumors","volume":"83","author":"Logothetis","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008287814252_bb0125","first-page":"221","article-title":"A 61% response rate with 5-fluorouracil, interferon-2\u03b1 and cisplatin in metastatic chemotherapy refractory transitional cell carcinoma","volume":"33","author":"Logothetis","year":"1992","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1023\/A:1008287814252_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1023\/A:1008287814252_bb0135","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ssu.2980080511","article-title":"Chemotherapy for urothelial tract malignancies: Breaking the deadlock (review)","volume":"8","author":"Scher","year":"1992","journal-title":"Semin Surg Oncol"},{"key":"10.1023\/A:1008287814252_bb0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-5347(17)48996-8","article-title":"Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium","volume":"133","author":"Sternberg","year":"1985","journal-title":"J Urol"},{"key":"10.1023\/A:1008287814252_bb0145","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1200\/JCO.1995.13.9.2272","article-title":"Escalated MVAC with or without recombinant human granulocyte macrophage colony stimulating factor for the initial treatment of advanced malignant urothelial tumors. Results of a randomized trial","volume":"13","author":"Logothetis","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008287814252_bb0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1464-410X.1992.tb15696.x","article-title":"Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma-response rate and pitfalls: MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party)","volume":"70","author":"Fossa","year":"1992","journal-title":"Br J Urol"},{"key":"10.1023\/A:1008287814252_bb0155","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.1994.12.11.2264","article-title":"Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group","volume":"12","author":"Roth","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008287814252_bb0160","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S0022-5347(01)66765-X","article-title":"Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies","volume":"154","author":"Tu","year":"1995","journal-title":"J Urol"},{"key":"10.1023\/A:1008287814252_bb0165","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/1097-0142(19911215)68:12<2561::AID-CNCR2820681205>3.0.CO;2-G","article-title":"Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors","volume":"68","author":"Seidman","year":"1991","journal-title":"Cancer"},{"key":"10.1023\/A:1008287814252_bb0170","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.1994.12.11.2271","article-title":"Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma","volume":"12","author":"Einhorn","year":"1994","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419605429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419605429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/8\/4\/373\/19480821\/8-4-373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T01:03:22Z","timestamp":1582247002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419605429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,4]]}},"alternative-id":["S0923753419605429"],"URL":"https:\/\/doi.org\/10.1023\/a:1008287814252","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1997,4]]}}}